Pharmafile Logo

ISMPP EU

- PMLiVE

Personalised medicine can improve treatment, but access still an issue

Barriers to access could harm uptake of potentially transformative therapies

- PMLiVE

Teva names new CFO and bulks up its opioid liability fund

Opioid liability issue overshadowed the company's Q3 results

Understanding the evolving CAR-T market

In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Blue Latitude Health

- PMLiVE

J&J catches up to Merck, files Ebola vaccine in Europe

Company is also in discussion with the FDA in the US to support regulatory filings

- PMLiVE

The long and winding road to asthma breakthroughs

Respiratory biologics are booming thanks to scientists who refused to be derailed by early research setbacks

- PMLiVE

OPEN Health expands global footprint with Pharmerit International integration

Global health comms and market access group now has presence in six countries

- PMLiVE

Takeda’s dengue vaccine seems safe with no prior virus exposure

Appears unaffected by serious safety issue affecting Sanofi rival

- PMLiVE

NICE International relaunches, will offer advisory services

Meets growing demand from global health and social care organisations

- PMLiVE

Indegene Pharma Marketer 2020 Report predicts significant shift in channel spends

Content personalisation to continue to yield disproportionate returns

- PMLiVE

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Will pay $100m upfont and pledges $210m in milestone payments

- PMLiVE

W2O continues global expansion with ISO.health acquisition

Acquisition of London-based agency extends reach into Europe

- PMLiVE

Evotec and Vifor announce joint venture for kidney disease treatments

Both companies will split the clinical and commercial costs equally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links